# Allan D Struthers

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3796854/publications.pdf

Version: 2024-02-01

| 282 | 14,934 | 15504 65 | 22166 113 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 285 | 285 | 285 | 14525 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Effect of perindopril or leucine on physical performance in older people with sarcopenia: the LACE randomized controlled trial. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 858-871. | 7.3 | 13 |
| 2 | A Randomized, Controlled Trial of the Effect of Allopurinol on Left Ventricular Mass Index in Hemodialysis Patients. Kidney International Reports, 2021, 6, 146-155. | 0.8 | 8 |
| 3 | Recruitment strategies for sarcopenia trials: lessons from the LACE randomized controlled trial. JCSM Rapid Communications, 2021, 4, 93-102. | 1.6 | 8 |
| 4 | Letter by Singh et al Regarding Article, â€œEffect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)â€. Circulation, 2021, 144, e38-e39. | 1.6 | 1 |
| 5 | Association between mitochondrial function measured by 31P magnetic resonance spectroscopy and physical performance in older people with functional impairment. JCSM Clinical Reports, 2021, 6, 71-79. | 1.3 | 0 |
| 6 | Reply. Journal of Hypertension, 2020, 38, 177-178. | 0.5 | 0 |
| 7 | Vitamin K Supplementation to Improve Vascular Stiffness in CKD: The K4Kidneys Randomized Controlled Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 2434-2445. | 6.1 | 49 |
| 8 | Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure. Circulation, 2020, 142, 1713-1724. | 1.6 | 144 |
| 9 | Allopurinol in Patients with Pulmonary Hypertension Associated with Chronic Lung Disease . International Journal of COPD, 2020, Volume 15, 2015-2024. | 2.3 | 3 |
| 10 | Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial. Diabetes Care, 2020, 43, 1356-1359. | 8.6 | 102 |
| 11 | A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. European Heart Journal, 2020, 41, 3421-3432. | 2.2 | 138 |
| 12 | Effect of allopurinol on phosphocreatine recovery and muscle function in older people with impaired physical function: a randomised controlled trial. Age and Ageing, 2020, 49, 1003-1010. | 1.6 | 5 |
| 13 | Cardiovascular Effects of Switching FromÂTobacco Cigarettes to ElectronicÂCigarettes. Journal of the American College of Cardiology, 2019, 74, 3112-3120. | 2.8 | 143 |
| 14 | A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. European Heart Journal, 2019, 40, 3409-3417. | 2.2 | 100 |
| 15 | Allopurinol treatment adversely impacts left ventricular mass regression in patients with well-controlled hypertension. Journal of Hypertension, 2019, 37, 2481-2489. | 0.5 | 17 |
| 16 | Pentaerythrityl tetranitrate (PETN): a better nitrate?. European Heart Journal, 2019, 40, e23-e25. | 2.2 | 3 |
| 17 | Effects of contrast administration on cardiac MRI volumetric, flow and pulse wave velocity quantification using manual and software-based analysis. British Journal of Radiology, 2018, 91, 20170717. | 2.2 | 8 |
| 18 | Pulmonary arterial stiffening in COPD and its implications for right ventricular remodelling. European Radiology, 2018, 28, 3464-3472. | 4.5 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Prevalence and Distribution of Atherosclerosis in a Low- to Intermediate-Risk Population: Assessment with Whole-Body MR Angiography. Radiology, 2018, 287, 795-804. | 7.3 | 7 |
| 20 | Development and Validation of a Path Length Calculation for Carotidâ€“Femoral Pulse Wave Velocity Measurement. Hypertension, 2018, 71, 937-945. | 2.7 | 19 |
| 21 | The <scp>APEX</scp> trial: Effects of allopurinol on exercise capacity, coronary and peripheral endothelial function, and natriuretic peptides in patients with cardiac syndrome X. Cardiovascular Therapeutics, 2018, 36, e12311. | 2.5 | 8 |
| 22 | The effect of perindopril on postural instability in older people with a history of fallsâ€”a randomised controlled trial. Age and Ageing, 2018, 47, 75-81. | 1.6 | 12 |
| 23 | Xanthine oxidase inhibition for the improvement of long-term outcomes following ischaemic stroke and transient ischaemic attack (XILO-FIST) â€“ Protocol for a randomised double blind placebo-controlled clinical trial. European Stroke Journal, 2018, 3, 281-290. | 5.5 | 26 |
| 24 | FP802EFFECT OF ALLOPURINOL ON LEFT VENTRICULAR MASS INDEX IN HAEMODIALYSIS PATIENTS - A RANDOMISED CONTROLLED TRIAL. Nephrology Dialysis Transplantation, 2018, 33, i633-i633. | 0.7 | 0 |
| 25 | Effect of Vitamin D Supplementation on Markers of Vascular Function: A Systematic Review and Individual Participant Metaâ€Analysis. Journal of the American Heart Association, 2018, 7, . | 3.7 | 63 |
| 26 | 6â€…Metformin regresses left ventricular hypertrophy in normotensive patients with coronary artery disease without type 2 diabetes mellitus â€“ the met-remodel trial. , 2018, , . | | 5 |
| 27 | Disconnection of pulmonary and systemic arterial stiffness in COPD. International Journal of COPD, 2018, Volume 13, 1755-1765. | 2.3 | 7 |
| 28 | Acceptability and feasibility of magnetic femoral nerve stimulation in older, functionally impaired patients. BMC Research Notes, 2018, 11, 394. | 1.4 | 1 |
| 29 | Systemic arteriosclerosis is associated with left ventricular remodeling but not atherosclerosis: a TASCFORCE study. Journal of Cardiovascular Magnetic Resonance, 2018, 20, 7. | 3.3 | 7 |
| 30 | Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomised controlled trial. Trials, 2018, 19, 6. | 1.6 | 39 |
| 31 | Research cardiac magnetic resonance imaging in end stage renal disease - incidence, significance and implications of unexpected incidental findings. European Radiology, 2017, 27, 315-324. | 4.5 | 5 |
| 32 | An Openâ€Label Doseâ€Finding Study of Allopurinol to Target Defined Reduction in Urate Levels in Hemodialysis Patients. Journal of Clinical Pharmacology, 2017, 57, 1409-1414. | 2.0 | 5 |
| 33 | Myocardial changes in incident haemodialysis patients over 6-months: an observational cardiac magnetic resonance imaging study. Scientific Reports, 2017, 7, 13976. | 3.3 | 6 |
| 34 | Renal and Cardiovascular Effects of sodiumâ€“glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. BMJ Open, 2017, 7, e018097. | 1.9 | 38 |
| 35 | Twentyâ€Year Predictors of Peripheral Arterial Disease Compared With Coronary Heart Disease in the Scottish Heart Health Extended Cohort (SHHEC). Journal of the American Heart Association, 2017, 6, . | 3.7 | 54 |
| 36 | Association between GDF-15 levels and changes in vascular and physical function in older patients with hypertension. Aging Clinical and Experimental Research, 2017, 29, 1055-1059. | 2.9 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | 15â€...No association between systemic arteriosclerosis and atherosclerosis on cardiac MRI and whole body angiography: the tascforce study. , 2017, , . | | 0 |
| 38 | Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study. BMC Cardiovascular Disorders, 2017, 17, 229. | 1.7 | 25 |
| 39 | Letter to the editor: Comparing pace and speed in the pulmonary circulation?. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H949-H949. | 3.2 | 1 |
| 40 | TO034NON-CONTRAST CARDIAC MAGNETIC RESONANCE T1 MAPPING AS A MARKER OF MYOCARDIAL FIBROSIS IN END STAGE RENAL DISEASE. Nephrology Dialysis Transplantation, 2016, 31, i75-i75. | 0.7 | 0 |
| 41 | Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovascular Diabetology, 2016, 15, 97. | 6.8 | 49 |
| 42 | Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study. BMJ Open, 2016, 6, e013774. | 1.9 | 70 |
| 43 | The Incidence and Risk of Biochemical Recurrence Following Radical Radiotherapy for Prostate Cancer in Men on Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs). Clinical Genitourinary Cancer, 2016, 14, 398-405. | 1.9 | 8 |
| 44 | Defining myocardial tissue abnormalities in end-stage renal failure with cardiac magnetic resonance imaging using native T1 mapping. Kidney International, 2016, 90, 845-852. | 5.2 | 88 |
| 45 | Spironolactone for People Age 70 Years and Older With Osteoarthritic Knee Pain: A Proofâ€ofâ€Concept Trial. Arthritis Care and Research, 2016, 68, 716-721. | 3.4 | 3 |
| 46 | Prevalence of unrecognized myocardial infarction in a lowâ€“intermediate risk asymptomatic cohort and its relation to systemic atherosclerosis. European Heart Journal Cardiovascular Imaging, 2016, 18, jew155. | 1.2 | 10 |
| 47 | Left Ventricular Noncompaction. Journal of the American College of Cardiology, 2016, 68, 2157-2165. | 2.8 | 118 |
| 48 | Assessment of proximal pulmonary arterial stiffness using magnetic resonance imaging: effects of technique, age and exercise. BMJ Open Respiratory Research, 2016, 3, e000149. | 3.0 | 6 |
| 49 | 015â€...Prevalence, pattern and significance of late gadolinium enhancement in a healthy asymptomatic cohort. Heart, 2016, 102, A5.3-A5. | 2.9 | 0 |
| 50 | 014â€...Patterns of early atherosclerosis formation and cardiac remodelling in healthy adults of south asian and european descent. Heart, 2016, 102, A5.2-A5. | 2.9 | 0 |
| 51 | Follow-up of atheroma burden with sequential whole body contrast enhanced MR angiography: a feasibility study. International Journal of Cardiovascular Imaging, 2016, 32, 825-832. | 1.5 | 3 |
| 52 | Whole body cardiovascular magnetic resonance imaging to stratify symptomatic and asymptomatic atherosclerotic burden in patients with isolated cardiovascular disease. BMC Medical Imaging, 2016, 16, 18. | 2.7 | 6 |
| 53 | 3T MRI investigation of cardiac left ventricular structure and function in a UK population: The tayside screening for the prevention of cardiac events (TASCFORCE) study. Journal of Magnetic Resonance Imaging, 2016, 44, 1186-1196. | 3.4 | 11 |
| 54 | Whole-body cardiovascular MRI for the comparison of atherosclerotic burden and cardiac remodelling in healthy South Asian and European adults. British Journal of Radiology, 2016, 89, 20160342. | 2.2 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Mean <scp>HbA<sub>1c</sub></scp> and mortality in diabetic individuals with heart failure: a population cohort study. European Journal of Heart Failure, 2016, 18, 94-102. | 7.1 | 76 |
| 56 | MRI of the left atrium at 3T: evaluation of measurement reproducibility in healthy volunteers and patients with cardiovascular disease. Acta Radiologica, 2016, 57, 1468-1475. | 1.1 | 2 |
| 57 | A Randomized Controlled Trial of Allopurinol in Patients With Peripheral Arterial Disease. Canadian Journal of Cardiology, 2016, 32, 190-196. | 1.7 | 11 |
| 58 | Both High and Low HbA1c Predict Incident Heart Failure in Type 2 Diabetes Mellitus. Circulation: Heart Failure, 2015, 8, 236-242. | 3.9 | 41 |
| 59 | Aortic remodelling following the treatment and regression of hypertensive left ventricular hypertrophy: a cardiovascular magnetic resonance study. Clinical and Experimental Hypertension, 2015, 37, 308-316. | 1.3 | 21 |
| 60 | Impact of Left Ventricular Hypertrophy on Survival in Chronic Obstructive Pulmonary Disease. Lung, 2015, 193, 487-495. | 3.3 | 7 |
| 61 | Effect of Vitamin D Supplementation on Blood Pressure. JAMA Internal Medicine, 2015, 175, 745. | 5.1 | 272 |
| 62 | High B-Type Natriuretic Peptide Hypertensives at Target Blood Pressure. Hypertension, 2015, 66, 927-932. | 2.7 | 3 |
| 63 | The role of pulmonary arterial stiffness in COPD. Respiratory Medicine, 2015, 109, 1381-1390. | 2.9 | 46 |
| 64 | An Increased B-Type Natriuretic Peptide inÂthe Absence of a Cardiac Abnormality Identifies Those Whose Left Ventricular Mass Will Increase Over Time. JACC: Heart Failure, 2015, 3, 87-93. | 4.1 | 10 |
| 65 | Common Carotid Intima Media Thickness and Ankle-Brachial Pressure Index Correlate with Local but Not Global Atheroma Burden: A Cross Sectional Study Using Whole Body Magnetic Resonance Angiography. PLoS ONE, 2014, 9, e99190. | 2.5 | 19 |
| 66 | Do ACE Inhibitors Improve the Response to Exercise Training in Functionally Impaired Older Adults? A Randomized Controlled Trial. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69, 736-743. | 3.6 | 65 |
| 67 | High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. European Heart Journal, 2014, 35, 271-281. | 2.2 | 160 |
| 68 | Myocardial ischaemia is associated with an elevated brain natriuretic pepide level even in the presence of left ventricular systolic dysfunction. European Journal of Heart Failure, 2014, 16, 56-67. | 7.1 | 6 |
| 69 | High BNP levels in rheumatoid arthritis are related to inflammation but not to left ventricular abnormalities: A prospective caseâ€“control study. International Journal of Cardiology, 2014, 172, e116-e118. | 1.7 | 14 |
| 70 | Novel Blockers of the Renin-Angiotensin-Aldosterone System in Chronic Heart Failure. Current Heart Failure Reports, 2014, 11, 31-39. | 3.3 | 3 |
| 71 | Vitamin D Therapy to Reduce Blood Pressure and Left Ventricular Hypertrophy in Resistant Hypertension. Hypertension, 2014, 63, 706-712. | 2.7 | 57 |
| 72 | High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study. Heart, 2014, 100, 867-872. | 2.9 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respiratory Medicine,the, 2014, 2, 293-300. | 10.7 | 94 |
| 74 | Effect of vitamin D supplementation on orthostatic hypotension. Journal of Hypertension, 2014, 32, 1693-1699. | 0.5 | 12 |
| 75 | Effect of Spironolactone on Physical Performance in Older People with Self-reported Physical Disability. American Journal of Medicine, 2013, 126, 590-597. | 1.5 | 16 |
| 76 | Cholecalciferol Treatment to Reduce Blood Pressure in Older Patients With Isolated Systolic Hypertension. JAMA Internal Medicine, 2013, 173, 1672-9. | 5.1 | 123 |
| 77 | Allopurinol Reduces Left Ventricular Mass in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy. Journal of the American College of Cardiology, 2013, 62, 2284-2293. | 2.8 | 97 |
| 78 | High-Dose Allopurinol Reduces Left Ventricular Mass in Patients With Ischemic Heart Disease. Journal of the American College of Cardiology, 2013, 61, 926-932. | 2.8 | 132 |
| 79 | Effects of Vitamin D supplementation on markers of vascular function after myocardial infarctionâ€"A randomised controlled trial. International Journal of Cardiology, 2013, 167, 745-749. | 1.7 | 60 |
| 80 | Targeting the reninâ€"angiotensinâ€"aldosterone system in heart failure. Nature Reviews Cardiology, 2013, 10, 125-134. | 13.7 | 78 |
| 81 | Aortic valvular heart disease: is there a place for angiotensin-converting-enzyme inhibitors?. Expert Review of Cardiovascular Therapy, 2013, 11, 107-114. | 1.5 | 8 |
| 82 | A New Approach to Residual Risk in Treated Hypertensionâ€"3P Screening. Hypertension, 2013, 62, 236-239. | 2.7 | 15 |
| 83 | Left Ventricular Hypertrophy in COPD Without Hypoxemia. Chest, 2013, 143, 91-97. | 0.8 | 26 |
| 84 | The prognostic value of high sensitivity troponin T 7 weeks after an acute coronary syndrome. Heart, 2012, 98, 1160-1165. | 2.9 | 20 |
| 85 | B-type natriuretic peptide is an independent predictor of endothelial function in man. Clinical Science, 2012, 123, 307-312. | 4.3 | 24 |
| 86 | Efficacy and Cost of an Exercise Program for Functionally Impaired Older Patients With Heart Failure. Circulation: Heart Failure, 2012, 5, 209-216. | 3.9 | 57 |
| 87 | The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. European Journal of Heart Failure, 2012, 14, 1303-1310. | 7.1 | 79 |
| 88 | Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. European Heart Journal, 2012, 33, 2782-2795. | 2.2 | 148 |
| 89 | Hypertensive left ventricular hypertrophy. Journal of Hypertension, 2012, 30, 2039-2046. | 0.5 | 24 |
| 90 | Pulmonary hypertension predicts allâ€cause mortality in patients with heart failure: a retrospective cohort study. European Journal of Heart Failure, 2012, 14, 162-167. | 7.1 | 48 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Insulin Sensitization Therapy and the Heart. Heart Failure Clinics, 2012, 8, 539-550. | 2.1 | 14 |
| 92 | Reninâ€“angiotensin system blockers are associated with reduced mortality and heart failure hospitalization in patients paced for complete atrioventricular block. Heart Rhythm, 2012, 9, 505-510. | 0.7 | 5 |
| 93 | Improving the Primary Prevention of Cardiovascular Events by Using Biomarkers to Identify Individuals With Silent Heart Disease. Journal of the American College of Cardiology, 2012, 60, 960-968. | 2.8 | 75 |
| 94 | Allopurinol: novel indications in cardiovascular disease. Heart, 2012, 98, 1543-1545. | 2.9 | 27 |
| 95 | Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. Arthritis and Rheumatism, 2012, 64, 327-338. | 6.7 | 58 |
| 96 | Mechanistic Insights Into the Therapeutic Use of High-Dose Allopurinol in Angina Pectoris. Journal of the American College of Cardiology, 2011, 58, 820-828. | 2.8 | 110 |
| 97 | Impact of Renin-Angiotensin System Blockade Therapy on Outcome in Aortic Stenosis. Journal of the American College of Cardiology, 2011, 58, 570-576. | 2.8 | 142 |
| 98 | The Impact of Renin-Angiotensin-Aldosterone System Blockade on Heart Failure Outcomes and Mortality in Patients Identified to Have Aortic Regurgitation. Journal of the American College of Cardiology, 2011, 58, 2084-2091. | 2.8 | 68 |
| 99 | Global Array-Based Transcriptomics from Minimal Input RNA Utilising an Optimal RNA Isolation Process Combined with SPIA cDNA Probes. PLoS ONE, 2011, 6, e17625. | 2.5 | 3 |
| 100 | Impact of allopurinol use on urate concentration and cardiovascular outcome. British Journal of Clinical Pharmacology, 2011, 71, 600-607. | 2.4 | 82 |
| 101 | Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people?. Clinical Endocrinology, 2011, 75, 725-729. | 2.4 | 34 |
| 102 | Meta-Analysis of B-Type Natriuretic Peptide's Ability to Identify Stress Induced Myocardial Ischemia. American Journal of Cardiology, 2011, 107, 662-667. | 1.6 | 35 |
| 103 | N-Terminal Pro-Brain Natriuretic Protein Levels in Takotsubo Cardiomyopathy. American Journal of Cardiology, 2011, 108, 1316-1321. | 1.6 | 123 |
| 104 | Family history of premature coronary heart disease and risk prediction. Heart, 2011, 97, 684-684. | 2.9 | 6 |
| 105 | Allopurinol Benefits Left Ventricular Mass and Endothelial Dysfunction in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2011, 22, 1382-1389. | 6.1 | 191 |
| 106 | Right ventricular pacing impairs endothelial function in man. Europace, 2011, 13, 853-858. | 1.7 | 9 |
| 107 | Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. Journal of Hypertension, 2010, 28, 170-177. | 0.5 | 27 |
| 108 | C-type natriuretic peptide production by the human kidney is blunted in chronic heart failure. Clinical Science, 2010, 118, 71-77. | 4.3 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Polymorphisms of the angiotensin converting enzyme gene in relation to intrauterine growth restriction. Acta Obstetricia Et Gynecologica Scandinavica, 2010, 89, 1197-1201. | 2.8 | 2 |
| 110 | Effect of Metformin on Mortality in Patients With Heart Failure and Type 2 Diabetes Mellitus. American Journal of Cardiology, 2010, 106, 1006-1010. | 1.6 | 89 |
| 111 | Reducing Cardiovascular Risk in Patients following MI with Eplerenone. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S5231. | 0.4 | 0 |
| 112 | Response to Letter Regarding Article, â€œThe Effects of Vitamin D Supplementation on Physical Function and Quality of Life in Older Heart Failure Patients: A Randomized Controlled Trialâ€. Circulation: Heart Failure, 2010, 3, . | 3.9 | 1 |
| 113 | Preoperative NT-proBNP and CRP predict perioperative major cardiovascular events in non-cardiac surgery. Heart, 2010, 96, 1254-1254. | 2.9 | 0 |
| 114 | Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ: British Medical Journal, 2010, 340, c1768-c1768. | 2.3 | 83 |
| 115 | Polymorphisms of the angiotensin converting enzyme gene in early-onset and late-onset pre-eclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2010, 23, 874-879. | 1.5 | 19 |
| 116 | The Effects of Vitamin D Supplementation on Physical Function and Quality of Life in Older Patients With Heart Failure. Circulation: Heart Failure, 2010, 3, 195-201. | 3.9 | 199 |
| 117 | Chronic Cardiac Failure. , 2010, , 272-285. | | 1 |
| 118 | Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet, The, 2010, 375, 2161-2167. | 13.7 | 301 |
| 119 | High-dose allopurinol in patients with stable angina pectoris â€“ Authors' reply. Lancet, The, 2010, 376, 1299-1300. | 13.7 | 0 |
| 120 | The role of urate and xanthine oxidase in vascular oxidative stress: future directions. Therapeutics and Clinical Risk Management, 2009, 5, 799. | 2.0 | 25 |
| 121 | Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vascular Health and Risk Management, 2009, 5, 265. | 2.3 | 167 |
| 122 | Adherence to angiotensinâ€converting enzyme inhibitors and illness beliefs in older heart failure patients. European Journal of Heart Failure, 2009, 11, 715-720. | 7.1 | 23 |
| 123 | A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure, 2009, 11, 980-989. | 7.1 | 32 |
| 124 | Effect of vitamin D on blood pressure: a systematic review and meta-analysis. Journal of Hypertension, 2009, 27, 1948-1954. | 0.5 | 320 |
| 125 | Optimization of the contrast dose and injection rates in wholeâ€body MR angiography at 3.0T. Journal of Magnetic Resonance Imaging, 2009, 30, 1059-1067. | 3.4 | 15 |
| 126 | Serial bedside B-type natriuretic peptide strongly predicts prognosis in acute coronary syndrome independent of echocardiographic abnormalities. American Heart Journal, 2009, 158, 133-140. | 2.7 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | The OPT-CHF (Oxypurinol Therapy for Congestive Heart Failure) Trial. Journal of the American College of Cardiology, 2009, 53, 2405. | 2.8 | 14 |
| 128 | Insulin Resistance Is Highly Prevalent and Is Associated With Reduced Exercise Tolerance in Nondiabetic Patients With Heart Failure. Journal of the American College of Cardiology, 2009, 53, 747-753. | 2.8 | 84 |
| 129 | Therapeutic Development in Cardiac Syndrome X: A Need to Target the Underlying Pathophysiology. Cardiovascular Therapeutics, 2009, 27, 49-58. | 2.5 | 26 |
| 130 | Serial changes in adiponectin and BNP in ACS patients: paradoxical associations with each other and with prognosis. Clinical Science, 2009, 117, 41-48. | 4.3 | 17 |
| 131 | Using the demand-control model of job strain to predict caregiver burden and caregiver satisfaction in the informal caregivers of heart failure patients. British Journal of Health Psychology, 2008, 13, 401-417. | 3.5 | 17 |
| 132 | A Comparison of the Aldosteroneâ€blocking Agents Eplerenone and Spironolactone. Clinical Cardiology, 2008, 31, 153-158. | 1.8 | 196 |
| 133 | The Role of Urate and Xanthine Oxidase Inhibitors in Cardiovascular Disease. Cardiovascular Drug Reviews, 2008, 26, 59-64. | 4.1 | 33 |
| 134 | Biomarkers and Surrogate Endpoints in Cardiovascular Therapeutics Research: Under Scrutiny Following Results of the ENHANCE Study. Cardiovascular Therapeutics, 2008, 26, 85-88. | 2.5 | 5 |
| 135 | Correlation of angiotensin converting enzyme activity and the genotypes of the I/D polymorphism in the ACE gene with preterm birth and birth weight. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2008, 141, 27-30. | 1.1 | 15 |
| 136 | The association between serum urate levels and arterial stiffness/endothelial function in stroke survivors. Atherosclerosis, 2008, 200, 374-379. | 0.8 | 21 |
| 137 | Assessment of Arterial Stiffness, A Translational Medicine Biomarker System for Evaluation of Vascular Risk. Cardiovascular Therapeutics, 2008, 26, 214-223. | 2.5 | 89 |
| 138 | Allopurinol Treatment Reduces Arterial Wave Reflection in Stroke Survivors. Cardiovascular Therapeutics, 2008, 26, 247-252. | 2.5 | 42 |
| 139 | Adverse Cardiovascular Effects of Acute Salt Loading in Young Normotensive Individuals. Hypertension, 2008, 51, 1525-1530. | 2.7 | 113 |
| 140 | Review: Aldosterone antagonism in type 2 diabetes mellitus â€" a new therapeutic approach to diabetic macrovascular disease?. British Journal of Diabetes and Vascular Disease, 2008, 8, 16-19. | 0.6 | 0 |
| 141 | Development and Validation of a Clinical Score to Identify Echocardiographic Left Ventricular Hypertrophy in Patients With Cardiovascular Disease. American Journal of Hypertension, 2008, 21, 1011-1017. | 2.0 | 10 |
| 142 | Uric acid in chronic heart failureâ€"current pathophysiological concepts*. European Journal of Heart Failure, 2008, 10, 1269-1270. | 7.1 | 15 |
| 143 | Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. Expert Opinion on Pharmacotherapy, 2007, 8, 3053-3059. | 1.8 | 15 |
| 144 | A critical re-appraisal of different ways of selecting ambulatory patients with suspected heart failure for echocardiography. European Journal of Heart Failure, 2007, 9, 55-61. | 7.1 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent 'pancardiac' target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney. European Heart Journal, 2007, 28, 1678-1682. | 2.2 | 61 |
| 146 | Longâ€Term Followâ€Up of Very Old Heart Failure Patients Enrolled in a Trial of Exercise Training. The American Journal of Geriatric Cardiology, 2007, 16, 243-248. | 0.6 | 10 |
| 147 | Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. Cmaj, 2007, 177, 867-874. | 2.0 | 212 |
| 148 | Response to Letter Regarding Article, â€œHigh-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acidâ€. Circulation, 2007, 115, . | 1.6 | 0 |
| 149 | Left ventricular hypertrophy is present in one-half of newly-diagnosed peripheral arterial disease patients. Journal of Hypertension, 2007, 25, 463-469. | 0.5 | 7 |
| 150 | Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. Journal of Hypertension, 2007, 25, 2345-2351. | 0.5 | 34 |
| 151 | The Cardiovascular Risk Factor, Left Ventricular Hypertrophy, Is Highly Prevalent in Stable, Treated Angina Pectoris. American Journal of Hypertension, 2007, 20, 1029-1035. | 2.0 | 22 |
| 152 | The influence of mode of delivery and ACE genotype on serum angiotensin converting enzyme (ACE) activity in the mother and infant at term. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2007, 134, 179-183. | 1.1 | 5 |
| 153 | Effect of spironolactone on C-reactive protein levels in patients with heart disease. International Journal of Cardiology, 2007, 117, 282-284. | 1.7 | 21 |
| 154 | Natriuretic Peptides. , 2007, , 349-362. | | 4 |
| 155 | The Functional Consequence of the Glu298Asp Polymorphism of the Endothelial Nitric Oxide Synthase Gene in Young Healthy Volunteers. Cardiovascular Drug Reviews, 2007, 25, 280-288. | 4.1 | 42 |
| 156 | Does the aldosterone: renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study. BMC Cardiovascular Disorders, 2007, 7, 14. | 1.7 | 6 |
| 157 | Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus. Diabetologia, 2007, 50, 2061-2066. | 6.3 | 9 |
| 158 | Screening for left ventricular systolic dysfunction using GP-reported ECGs. British Journal of General Practice, 2007, 57, 191-5. | 1.4 | 8 |
| 159 | Predictors of exercise capacity and everyday activity in older heart failure patients. European Journal of Heart Failure, 2006, 8, 203-207. | 7.1 | 37 |
| 160 | Sarcopenia â€“ A Potential Target for Angiotensin-Converting Enzyme Inhibition?. Gerontology, 2006, 52, 237-242. | 2.8 | 43 |
| 161 | Letter by Struthers et al Regarding Article, â€œCross-Sectional Relations of Multiple Biomarkers From Distinct Biological Pathways to Brachial Artery Endothelial Functionâ€. Circulation, 2006, 114, e383; author reply e384. | 1.6 | 0 |
| 162 | Angiotensin blockade or aldosterone blockade as the third neuroendocrine-blocking drug in mild but symptomatic heart failure patients. Heart, 2006, 92, 1728-1731. | 2.9 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Effects of an exercise intervention for older heart failure patients on caregiver burden and emotional distress. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 381-387. | 2.8 | 17 |
| 164 | Aldosterone Blockade Over and Above ACE-Inhibitors in Patients with Coronary Artery Disease but without Heart Failure. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2006, 7, 20-30. | 1.7 | 12 |
| 165 | High-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acid. Circulation, 2006, 114, 2508-2516. | 1.6 | 492 |
| 166 | Effects of an exercise intervention for older heart failure patients on caregiver burden and emotional distress. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 381-387. | 2.8 | 22 |
| 167 | B-Type Natriuretic Peptide Is Associated with Mortality in Older Functionally Impaired Patients. Journal of the American Geriatrics Society, 2005, 53, 1991-1995. | 2.6 | 15 |
| 168 | Effect of a Seated Exercise Program to Improve Physical Function and Health Status in Frail Patients â‰¥70 Years of Age With Heart Failure. American Journal of Cardiology, 2005, 95, 1120-1124. | 1.6 | 99 |
| 169 | B-Type Natriuretic Peptide as an Alternative Way of Assessing Total Cardiovascular Risk in Patients With Diabetes Mellitus. American Journal of Cardiology, 2005, 96, 933-934. | 1.6 | 21 |
| 170 | Prevalence of Symptomatic Diastolic Heart Failure in Patients Hospitalized With Cerebral or Peripheral Vascular Disease. Congestive Heart Failure, 2005, 11, 256-261. | 2.0 | 2 |
| 171 | Autonomic Effects of Spironolactone and MR Blockers in Heart Failure. Heart Failure Reviews, 2005, 10, 63-69. | 3.9 | 8 |
| 172 | Do Losartan and Atenolol have Differential Effects on BNP and Central Haemodynamic Parameters?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2005, 6, 151-153. | 1.7 | 22 |
| 173 | Pathophysiology of heart failure following myocardial infarction. Heart, 2005, 91, ii14-ii16. | 2.9 | 25 |
| 174 | Beyond blood pressure: pulse wave analysis â€“ a better way of assessing cardiovascular risk?. Future Cardiology, 2005, 1, 69-78. | 1.2 | 18 |
| 175 | B-type natriuretic peptide: a simple new test to identify coronary artery disease?. QJM - Monthly Journal of the Association of Physicians, 2005, 98, 765-769. | 0.5 | 26 |
| 176 | Time course for recovery of atrial mechanical and endocrine function post DC cardioversion for persistent atrial fibrillation. International Journal of Cardiology, 2005, 102, 487-491. | 1.7 | 11 |
| 177 | Elevated levels of natriuretic peptides in patients with pulmonary thromboembolism. Respiratory Medicine, 2005, 99, 1286-1291. | 2.9 | 31 |
| 178 | B-Type Natriuretic Peptide Is Associated With Both Augmentation Index and Left Ventricular Mass in Diabetic Patients Without Heart Failure. American Journal of Hypertension, 2005, 18, 1586-1591. | 2.0 | 23 |
| 179 | Aldosterone blockade in heart failure.. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, S23. | 1.7 | 9 |
| 180 | Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovascular Research, 2004, 61, 663-670. | 3.8 | 229 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Effects of Exogenous and Endogenous Natriuretic Peptides on Forearm Vascular Function in Chronic Heart Failure. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 911-917. | 2.4 | 36 |
| 182 | The clinical implications of aldosterone escape in congestive heart failure. European Journal of Heart Failure, 2004, 6, 539-545. | 7.1 | 100 |
| 183 | Age is not a significant risk factor for failed trial of beta-blocker therapy in older patients with chronic heart failure. Age and Ageing, 2004, 33, 467-472. | 1.6 | 13 |
| 184 | Aldosterone blockade in cardiovascular disease. Heart, 2004, 90, 1229-1234. | 2.9 | 37 |
| 185 | Tolerability of spironolactone in patients with chronic heart failure - a cautionary message. British Journal of Clinical Pharmacology, 2004, 58, 554-557. | 2.4 | 28 |
| 186 | Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study. British Journal of Clinical Pharmacology, 2004, 57, 622-631. | 2.4 | 26 |
| 187 | Aldosterone in heart failure: Pathophysiology and treatment. Current Heart Failure Reports, 2004, 1, 171-175. | 3.3 | 13 |
| 188 | What is the optimal serum potassium level in cardiovascular patients?. Journal of the American College of Cardiology, 2004, 43, 155-161. | 2.8 | 288 |
| 189 | â€œSerum potassium level and risk of postoperative atrial fibrillation in patients undergoing cardiac surgeryâ€ Reply. Journal of the American College of Cardiology, 2004, 44, 939. | 2.8 | 0 |
| 190 | The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. Expert Review of Cardiovascular Therapy, 2004, 2, 29-36. | 1.5 | 3 |
| 191 | Aldosterone-induced vasculopathy. Molecular and Cellular Endocrinology, 2004, 217, 239-241. | 3.2 | 34 |
| 192 | How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade?. Journal of Hypertension, 2004, 22, 1403-1408. | 0.5 | 7 |
| 193 | Exercise Training as a Therapy for Chronic Heart Failure: Can Older People Benefit?. Journal of the American Geriatrics Society, 2003, 51, 699-709. | 2.6 | 35 |
| 194 | Hyperuricemia and Adverse Outcomes in Cardiovascular Disease. American Journal of Cardiovascular Drugs, 2003, 3, 309-314. | 2.2 | 17 |
| 195 | Myocardial Production of C-Type Natriuretic Peptide in Chronic Heart Failure. Circulation, 2003, 107, 571-573. | 1.6 | 171 |
| 196 | Diagnosis and management of heart failure: implications of the recent European Society of Cardiology Guidelines for the older patient. Age and Ageing, 2003, 32, 563-565. | 1.6 | 5 |
| 197 | Atrial Natriuretic Peptide Regulates Regional Vascular Volume and Venous Tone in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1833-1838. | 2.4 | 14 |
| 198 | Should we add screening for and treating left ventricular hypertrophy to the management of all patients needing secondary prevention of cardiovascular disease?. QJM - Monthly Journal of the Association of Physicians, 2003, 96, 449-452. | 0.5 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Screening for treatable left ventricular abnormalities in diabetic patients. Expert Opinion on Biological Therapy, 2003, 3, 107-112. | 3.1 | 7 |
| 200 | Pulse wave analysis and pulse wave velocity. Journal of Hypertension, 2003, 21, 463-472. | 0.5 | 257 |
| 201 | Peripheral blood pressure measurement is as good as applanation tonometry at predicting ascending aortic blood pressure. Journal of Hypertension, 2003, 21, 571-576. | 0.5 | 90 |
| 202 | Should hospitals have a designated consultant with a specific interest in heart failure?. QJM - Monthly Journal of the Association of Physicians, 2003, 96, 877-879. | 0.5 | 0 |
| 203 | Introducing a new role for BNP: as a general indicator of cardiac structural disease rather than a specific indicator of systolic dysfunction only. British Heart Journal, 2002, 87, 97-98. | 2.1 | 55 |
| 204 | Heart failure in frail elderly patients: diagnostic difficulties, coâ€morbidities, polypharmacy and treatment dilemmas. European Journal of Heart Failure, 2002, 4, 91-98. | 7.1 | 181 |
| 205 | Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure. Circulation, 2002, 106, 221-226. | 1.6 | 449 |
| 206 | Exercise Capacity and Brain Natruiretic Peptide in Hypertension. Journal of Cardiovascular Pharmacology, 2002, 40, 519-527. | 1.9 | 14 |
| 207 | B-type natriuretic peptide in the diagnosis of cardiac disease in elderly day hospital patients. Age and Ageing, 2002, 31, 295-301. | 1.6 | 27 |
| 208 | Lack of rapid aldosterone effects on forearm resistance vasculature in health. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 123-125. | 1.7 | 36 |
| 209 | Grossly elevated serum angiotensin-converting enzyme activities are still suppressible with ACE inhibitor therapy. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 138-138. | 1.7 | 0 |
| 210 | The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism?. Journal of Hypertension, 2002, 20, 11-15. | 0.5 | 59 |
| 211 | Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clinical Science, 2002, 103, 425-431. | 4.3 | 205 |
| 212 | The prevalence of treatable left ventricular systolic dysfunction in patients who present with noncardiac vascular episodes. Journal of the American College of Cardiology, 2002, 39, 219-224. | 2.8 | 31 |
| 213 | Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. Journal of the American College of Cardiology, 2002, 39, 767-775. | 2.8 | 59 |
| 214 | Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet, The, 2002, 359, 1430-1432. | 13.7 | 132 |
| 215 | Aldosterone: Cardiovascular assault. American Heart Journal, 2002, 144, S2-S7. | 2.7 | 75 |
| 216 | More evidence for bedside BNP in heart failure assessment. International Journal of Cardiology, 2002, 86, 149-152. | 1.7 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Review: The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 150-155. | 1.7 | 5 |
| 218 | Relation of QT interval dispersion to the number of different cardiac abnormalities in diabetes mellitus. American Journal of Cardiology, 2002, 90, 483-487. | 1.6 | 42 |
| 219 | Impact of Aldosterone on Vascular Pathophysiology. Congestive Heart Failure, 2002, 8, 18-22. | 2.0 | 29 |
| 220 | Evidence for myocardial synthesis of aldosterone producing myocardial fibrosis in man. Clinical Science, 2002, 102, 387. | 4.3 | 6 |
| 221 | The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus.. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 150. | 1.7 | 5 |
| 222 | Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. Journal of the American College of Cardiology, 2001, 37, 1800-1807. | 2.8 | 140 |
| 223 | Lisinopril improves endothelial function in chronic cigarette smokers. Clinical Science, 2001, 101, 53. | 4.3 | 13 |
| 224 | A placebo-controlled study examining the effect of allopurinol on heart rate variability and dysrhythmia counts in chronic heart failure. British Journal of Clinical Pharmacology, 2001, 51, 329-334. | 2.4 | 14 |
| 225 | Annual Scientific Meeting of ASCEPT, 1999 Careful Screening To Target Interventions To Prevent Sudden Cardiac Death. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 219-222. | 1.9 | 1 |
| 226 | Nonadherence with ACE Inhibitors Is Common and Can Be Detected in Clinical Practice by Routine Serum ACE Activity. Congestive Heart Failure, 2001, 7, 43-50. | 2.0 | 16 |
| 227 | Are Natriuretic Peptides Clinically Useful as Markers of Heart Failure?. Annals of Clinical Biochemistry, 2001, 38, 575-583. | 1.6 | 19 |
| 228 | Review: Aldosterone-induced vasculopathy: a new reversible cause of cardiac death. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, 211-214. | 1.7 | 12 |
| 229 | Adverse Cardiac Effects of Salt With Fludrocortisone in Hypertension. Hypertension, 2001, 37, 856-861. | 2.7 | 45 |
| 230 | Ovarian hormones in man: their effects on resting vascular tone, angiotensin converting enzyme activity and angiotensin II-induced vasoconstriction. British Journal of Clinical Pharmacology, 2000, 50, 73-76. | 2.4 | 7 |
| 231 | Pathophysiology of aldosterone and its antagonists. Fundamental and Clinical Pharmacology, 2000, 14, 549-552. | 1.9 | 4 |
| 232 | Effect of phenylephrine with and without atropine on QT dispersion in healthy normotensive men. American Journal of Cardiology, 2000, 85, 69-74. | 1.6 | 17 |
| 233 | Allopurinol Normalizes Endothelial Dysfunction in Type 2 Diabetics With Mild Hypertension. Hypertension, 2000, 35, 746-751. | 2.7 | 402 |
| 234 | Spironolactone Increases Nitric Oxide Bioactivity, Improves Endothelial Vasodilator Dysfunction, and Suppresses Vascular Angiotensin I/Angiotensin II Conversion in Patients With Chronic Heart Failure. Circulation, 2000, 101, 594-597. | 1.6 | 493 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | DD Angiotensin-Converting Enzyme Gene Polymorphism Is Associated With Endothelial Dysfunction in Normal Humans. Hypertension, 1999, 33, 1164-1168. | 2.7 | 102 |
| 236 | Irbesartan Reduces QT Dispersion in Hypertensive Individuals. Hypertension, 1999, 33, 713-718. | 2.7 | 52 |
| 237 | The effect of nitric oxide inhibition on the renin response to frusemide, in man. British Journal of Clinical Pharmacology, 1999, 48, 355-360. | 2.4 | 3 |
| 238 | Clinical case studies in heart failure management. British Journal of Clinical Pharmacology, 1999, 47, 239-247. | 2.4 | 0 |
| 239 | Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?. British Journal of Clinical Pharmacology, 1999, 47, 479-482. | 2.4 | 34 |
| 240 | Nonadherence with angiotensin-converting enzyme inhibitor therapy. Journal of the American College of Cardiology, 1999, 34, 2072-2077. | 2.8 | 32 |
| 241 | Lisinopril improves arterial function in hyperlipidaemia. Clinical Science, 1999, 96, 441-448. | 4.3 | 18 |
| 242 | Lisinopril improves arterial function in hyperlipidaemia. Clinical Science, 1999, 96, 441. | 4.3 | 4 |
| 243 | Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. European Journal of Heart Failure, 1999, 1, 401-406. | 7.1 | 62 |
| 244 | Nitric oxide: an important role in the maintenance of systemic and pulmonary vascular tone in man. British Journal of Clinical Pharmacology, 1998, 46, 263-266. | 2.4 | 12 |
| 245 | Cardiovascular consequences of laparoscopic surgery. Lancet, The, 1998, 352, 568-570. | 13.7 | 84 |
| 246 | Heart failure: a diagnostic and therapeutic dilemma in elderly patients. Age and Ageing, 1998, 27, 539-543. | 1.6 | 4 |
| 247 | Inhaled corticosteroid therapy reduces the early morning peak in cortisol and aldosterone. Clinical Science, 1998, 95, 513-517. | 4.3 | 5 |
| 248 | Inhaled corticosteroid therapy reduces the early morning peak in cortisol and aldosterone. Clinical Science, 1998, 95, 513. | 4.3 | 1 |
| 249 | Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet, The, 1997, 350, 1349-1353. | 13.7 | 775 |
| 250 | Enalapril Reduces QTc Dispersion in Mild Congestive Heart Failure Secondary to Coronary Artery Disease. American Journal of Cardiology, 1997, 79, 328-333. | 1.6 | 43 |
| 251 | The Practical Assessment of Compliance with ACE-Inhibitor Therapy-A Novel Approach. Journal of Cardiovascular Pharmacology, 1997, 29, 119-124. | 1.9 | 14 |
| 252 | Cross sectional study of contribution of clinical assessment and simple cardiac investigations to diagnosis of left ventricular systolic dysfunction in patients admitted with acute dyspnoea. BMJ: British Medical Journal, 1997, 314, 936-936. | 2.3 | 74 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. Journal of Cardiac Failure, 1996, 2, 47-54. | 1.7 | 200 |
| 254 | C-Type Natriuretic Peptide. Peptides, 1996, 17, 1243-1251. | 2.4 | 162 |
| 255 | Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. American Journal of Cardiology, 1996, 77, 828-831. | 1.6 | 181 |
| 256 | Diagnostic Value of B-Type Natriuretic Peptide Concentrations in Patients With Acute Myocardial Infarction. American Journal of Cardiology, 1996, 78, 284-287. | 1.6 | 123 |
| 257 | C-Type Natriuretic Peptide. Circulation, 1996, 93, 1155-1159. | 1.6 | 42 |
| 258 | Cyclosporin-induced renal vasoconstriction is augmented by frusemide and by angiotensin II in humans. Journal of Hypertension, 1995, 13, 987-991. | 0.5 | 6 |
| 259 | Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 days of cyclosporin therapy in males. Journal of Hypertension, 1995, 13, 667-673. | 0.5 | 27 |
| 260 | Comparative Effects of Atrial Natriuretic Peptide and Brain Natriuretic Peptide on the Aldosterone and Pressor Responses to Angiotensin Ii in Man. Clinical Science, 1995, 88, 81-86. | 4.3 | 17 |
| 261 | Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. American Journal of Cardiology, 1995, 76, 1259-1265. | 1.6 | 296 |
| 262 | Determinants of the initial effects of captopril on blood pressure, glomerular filtration rate, and natriuresis in mild-to-moderate chronic congestive heart failure secondary to coronary artery disease. American Journal of Cardiology, 1994, 73, 1191-1196. | 1.6 | 8 |
| 263 | Increased plasma levels of brain natriuretic peptide in patients with isolated diastolic dysfunction. American Heart Journal, 1994, 127, 1635-1636. | 2.7 | 112 |
| 264 | Brain natriuretic peptide. Journal of Hypertension, 1994, 12, 329???336. | 0.5 | 65 |
| 265 | The differential effects of circulating norepinephrine and neuronally released norepinephrine on sodium excretion in humans. Clinical Pharmacology and Therapeutics, 1993, 54, 514-522. | 4.7 | 4 |
| 266 | Effectiveness of captopril in reversing renal vasoconstriction after Q-wave acute myocardial infarction. American Journal of Cardiology, 1993, 71, 281-286. | 1.6 | 10 |
| 267 | Renal, hemodynamic and neurohormonal effects of atrial natriuretic factor in cardiac allograft recipients treated with cyclosporin A. American Journal of Cardiology, 1993, 72, 1083-1084. | 1.6 | 8 |
| 268 | Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure. American Heart Journal, 1993, 126, 879-886. | 2.7 | 32 |
| 269 | Enalapril blunts the antinatriuretic effect of circulating noradrenaline in man. Journal of Hypertension, 1993, 11, 565-572. | 0.5 | 5 |
| 270 | Effect of haemodialysis on plasma levels of brain natriuretic peptide in patients with chronic renal failure. Clinical Science, 1992, 82, 127-131. | 4.3 | 66 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Atrial and brain natriuretic peptides: a dual natriuretic peptide system potentially involved in circulatory homeostasis. Clinical Science, 1992, 83, 519-527. | 4.3 | 107 |
| 272 | Elevated levels of brain natriuretic peptide in acute hypoxaemic chronic obstructive pulmonary disease. Clinical Science, 1992, 83, 529-533. | 4.3 | 89 |
| 273 | Atrial natriuretic factor improves renal function and lowers systolic blood pressure in renal allograft recipients treated with cyclosporinA. Journal of Hypertension, 1992, 10, 483-488. | 0.5 | 16 |
| 274 | Prazosin blunts the antinatriuretic effect of circulating angiotensin II in man. Journal of Hypertension, 1992, 10, 1387-1395. | 0.5 | 9 |
| 275 | The clinical pharmacology of angiotensin converting enzyme inhibitors in chronic heart failure. , 1992, 53, 187-197. | | 11 |
| 276 | Prazosin attenuates the natriuretic response to atrial natriuretic factor in man. Kidney International, 1992, 42, 433-441. | 5.2 | 7 |
| 277 | Effect of pericardiocentesis on plasma levels of brain natriuretic peptide in cardiac tamponade. American Journal of Cardiology, 1992, 70, 1628-1629. | 1.6 | 7 |
| 278 | Dietary sodium loading increases plasma brain natriuretic peptide levels in man. Journal of Hypertension, 1991, 9, 779-782. | 0.5 | 66 |
| 279 | Angiotensin II augments sympathetically mediated arteriolar constriction in man. Clinical Science, 1991, 81, 261-266. | 4.3 | 42 |
| 280 | Interactions between atrial natriuretic factor and the autonomic nervous system. Clinical Autonomic Research, 1991, 1, 329-336. | 2.5 | 19 |
| 281 | Neuroendocrine changes post myocardial infarction: Effects of xamoterol. American Heart Journal, 1990, 120, 56-62. | 2.7 | 15 |
| 282 | Mechanisms of the antinatriuretic action of physiological doses of angiotensin II in man. Clinical Science, 1989, 76, 653-658. | 4.3 | 21 |